Literature DB >> 19461910

In pursuit of progress: multimodality strategies will form the cornerstone of cure for esophageal cancer.

Brian G Czito1, Christopher G Willett.   

Abstract

Entities:  

Year:  2009        PMID： 19461910      PMCID： PMC2684715     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  26 in total

1.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

Authors:  Katja Ott; Wolfgang A Weber; Florian Lordick; Karen Becker; Raymonde Busch; Ken Herrmann; Hinrich Wieder; Ulrich Fink; Markus Schwaiger; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

2.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Authors:  Laurent Bedenne; Pierre Michel; Olivier Bouché; Chantal Milan; Christophe Mariette; Thierry Conroy; Denis Pezet; Bernard Roullet; Jean-François Seitz; Jean-Philippe Herr; Bernard Paillot; Patrick Arveux; Franck Bonnetain; Christine Binquet
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

3.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

4.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

5.  A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.

Authors:  L E Gaspar; K Winter; W I Kocha; L R Coia; A Herskovic; M Graham
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

6.  Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.

Authors:  Howard Safran; Mohan Suntharalingam; Thomas Dipetrillo; Thomas Ng; L Austin Doyle; Mark Krasna; Angela Plette; Devon Evans; Harold Wanebo; Paul Akerman; Jeremy Spector; Nancy Kennedy; Teresa Kennedy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

8.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

Authors:  Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

9.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

Review 10.  Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.

Authors:  Richard A Malthaner; Rebecca Ks Wong; R Bryan Rumble; Lisa Zuraw
Journal:  BMC Med       Date:  2004-09-24       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.